Physician profile
Chaim Banjo
NPI 1588730121
$2,157.52
in general payments reported to CMS, 2019-2025
23 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $503 · 2021: $645 · 2022: $191 · 2023: $374 · 2024: $102 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.96 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.14 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Kvk-Tech, INC. | $259.97 | 2019-2022 | |
| Cmp Pharma, INC. | $244.85 | 2020-2023 | Carospir, Tadliq, Norliqva |
| Eisai INC. | $208.71 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $206.66 | 2019-2021 | |
| Pfizer INC. | $196.17 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $100.35 | 2022-2023 | Nexletol, Contrave |
| Abbvie INC. | $89.59 | 2021-2023 | Qulipta |
| Bausch Health US, LLC | $75.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.34 | 2022-2023 | Trintellix |
| Lilly USA, LLC | $42.46 | 2022-2023 | Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $36.13 | 2023 | Auvelity |
| Scilex Pharmaceuticals INC. | $35.52 | 2019 | |
| Horizon Therapeutics Plc | $23.64 | 2021 | |
| Abbott Laboratories | $22.97 | 2023 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $21.05 | 2023 | Telepatch Cardiac Monitor |
| Ultragenyx Pharmaceutical INC. | $19.58 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.32 | 2019 | |
| Amarin Pharma, INC. | $18.03 | 2019 | |
| Aytu Biopharma, INC. | $14.72 | 2020 | |
| Genentech USA, INC. | $12.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.82 | 2021 | |
| Allergan, INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaim Banjo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.